Moreover, the American Diabetes Association and the National guidelines recommend that a SGLT-2 inhibitor with demonstrated cardiovascular benefit be used in patients with established atherosclerotic cardiac disease, established kidney disease, or established heart failure. The gene discussed is SLC5A2; the disease is kidney disorder.